

## Disclosing material information.

Date	19/12/2024
Name of the Listed Company	Gulf Pharmaceutical Industries Julphar
The Material Information	The sale of 100% shareholding in DIABTEC LLC (human Insulin API manufacturing subsidiary)
The expected effect of material information on the financial position and results of the company's business and operations	<p>The subsidiary represents 12.6% of the consolidated total assets of the Julphar Group as of 30.09.2024. The transaction will be paid in cash at Closing and is expected to have a positive effect on the net profit/loss development of the company after Closing.</p> <p>The transaction includes the sale of the Insulin API manufacturing activities and does not impact Julphar's Insulin finished product business. As part of the transaction, Julphar is entering into a supply agreement with DiabTec to secure its Insulin API demand.</p> <p>The transaction is aligned with the company's strategic efforts to divest non-core assets, to expand its Diabetes portfolio and accelerate the launch of innovative Insulin products in the MENA region.</p> <p>The transaction is subject to customary completion formalities.</p>
The financial period in which the financial impact is expected to appear	Financial year 2024 or Q1 2025 depending on completing all customary completion formalities.

The Name of the Authorized Signatory	Khalid Malkawi
Designation	CFO
Signature and Date	